Placental proteins (SP1, hCG, PP5), and α2-PAG in trophoblastic diseases

G. Than, H. Bohn, I. F. Csaba, D. G. Szabó, N. J. Karg, P. Göcze

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

455 serial serum samples from 41 patients with trophoblastic tumour were analysed. Pregnancy-specific beta-1 glycoprotein (SP1), human chorionic gonadotropin (hCG), and placental protein 5 (PP5) were measured by specific radioimmunoassay. Pregnancy-associated α2-glycoprotein (α2-PAG) was measured by electroimmunoassay. SP1 and hCG levels were high in 36 and 35 patients respectively; α2-PAG concentration was also high in 29 patients. PP5 was found only in patients with a hydatidiform mole and it disappeared from serum within a few hours of evacuation. SP1 and hCG levels decreased during the course of the treatment but seronegativity was reached only after some months; hCG was still detectable after that and disappeared from the serum more slowly. Both parameters were sensitive indicators of residual tumour activity and indicated the need more effective treatment some months before clinical manifestations of recurrence became evident. In some patients only one of the tumour markers was present during follow-up, indicating the importance of careful monitoring including the measurement of serum SP1 and hCG levels. A positive correlation between α2-PAG and hCG, SP1 and the clinical course was found only in 80% of patients a finding which demonstrates the limited value of α2-PAG measurements.

Original languageEnglish
Pages (from-to)33-39
Number of pages7
JournalArchives of Gynecology
Volume231
Issue number1
DOIs
Publication statusPublished - Dec 1981

Fingerprint

Pregnancy Proteins
Chorionic Gonadotropin
Serum
Pregnancy-Specific beta 1-Glycoproteins
Trophoblastic Neoplasms
Hydatidiform Mole
Residual Neoplasm
Tumor Biomarkers
Radioimmunoassay
tissue-factor-pathway inhibitor 2
Recurrence
Therapeutics

Keywords

  • Follow-up investigations
  • Pregnancy and placental proteins
  • Pregnancy-specific and pregnancy-associated proteins
  • Trophoblastic tumours

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Medicine(all)

Cite this

Than, G., Bohn, H., Csaba, I. F., Szabó, D. G., Karg, N. J., & Göcze, P. (1981). Placental proteins (SP1, hCG, PP5), and α2-PAG in trophoblastic diseases. Archives of Gynecology, 231(1), 33-39. https://doi.org/10.1007/BF02110021

Placental proteins (SP1, hCG, PP5), and α2-PAG in trophoblastic diseases. / Than, G.; Bohn, H.; Csaba, I. F.; Szabó, D. G.; Karg, N. J.; Göcze, P.

In: Archives of Gynecology, Vol. 231, No. 1, 12.1981, p. 33-39.

Research output: Contribution to journalArticle

Than, G, Bohn, H, Csaba, IF, Szabó, DG, Karg, NJ & Göcze, P 1981, 'Placental proteins (SP1, hCG, PP5), and α2-PAG in trophoblastic diseases', Archives of Gynecology, vol. 231, no. 1, pp. 33-39. https://doi.org/10.1007/BF02110021
Than, G. ; Bohn, H. ; Csaba, I. F. ; Szabó, D. G. ; Karg, N. J. ; Göcze, P. / Placental proteins (SP1, hCG, PP5), and α2-PAG in trophoblastic diseases. In: Archives of Gynecology. 1981 ; Vol. 231, No. 1. pp. 33-39.
@article{8be2dac0d0f647ac88bfd5d21b121157,
title = "Placental proteins (SP1, hCG, PP5), and α2-PAG in trophoblastic diseases",
abstract = "455 serial serum samples from 41 patients with trophoblastic tumour were analysed. Pregnancy-specific beta-1 glycoprotein (SP1), human chorionic gonadotropin (hCG), and placental protein 5 (PP5) were measured by specific radioimmunoassay. Pregnancy-associated α2-glycoprotein (α2-PAG) was measured by electroimmunoassay. SP1 and hCG levels were high in 36 and 35 patients respectively; α2-PAG concentration was also high in 29 patients. PP5 was found only in patients with a hydatidiform mole and it disappeared from serum within a few hours of evacuation. SP1 and hCG levels decreased during the course of the treatment but seronegativity was reached only after some months; hCG was still detectable after that and disappeared from the serum more slowly. Both parameters were sensitive indicators of residual tumour activity and indicated the need more effective treatment some months before clinical manifestations of recurrence became evident. In some patients only one of the tumour markers was present during follow-up, indicating the importance of careful monitoring including the measurement of serum SP1 and hCG levels. A positive correlation between α2-PAG and hCG, SP1 and the clinical course was found only in 80{\%} of patients a finding which demonstrates the limited value of α2-PAG measurements.",
keywords = "Follow-up investigations, Pregnancy and placental proteins, Pregnancy-specific and pregnancy-associated proteins, Trophoblastic tumours",
author = "G. Than and H. Bohn and Csaba, {I. F.} and Szab{\'o}, {D. G.} and Karg, {N. J.} and P. G{\"o}cze",
year = "1981",
month = "12",
doi = "10.1007/BF02110021",
language = "English",
volume = "231",
pages = "33--39",
journal = "Archiv fur Gynakologie",
issn = "0932-0067",
publisher = "J.F. Bergmann",
number = "1",

}

TY - JOUR

T1 - Placental proteins (SP1, hCG, PP5), and α2-PAG in trophoblastic diseases

AU - Than, G.

AU - Bohn, H.

AU - Csaba, I. F.

AU - Szabó, D. G.

AU - Karg, N. J.

AU - Göcze, P.

PY - 1981/12

Y1 - 1981/12

N2 - 455 serial serum samples from 41 patients with trophoblastic tumour were analysed. Pregnancy-specific beta-1 glycoprotein (SP1), human chorionic gonadotropin (hCG), and placental protein 5 (PP5) were measured by specific radioimmunoassay. Pregnancy-associated α2-glycoprotein (α2-PAG) was measured by electroimmunoassay. SP1 and hCG levels were high in 36 and 35 patients respectively; α2-PAG concentration was also high in 29 patients. PP5 was found only in patients with a hydatidiform mole and it disappeared from serum within a few hours of evacuation. SP1 and hCG levels decreased during the course of the treatment but seronegativity was reached only after some months; hCG was still detectable after that and disappeared from the serum more slowly. Both parameters were sensitive indicators of residual tumour activity and indicated the need more effective treatment some months before clinical manifestations of recurrence became evident. In some patients only one of the tumour markers was present during follow-up, indicating the importance of careful monitoring including the measurement of serum SP1 and hCG levels. A positive correlation between α2-PAG and hCG, SP1 and the clinical course was found only in 80% of patients a finding which demonstrates the limited value of α2-PAG measurements.

AB - 455 serial serum samples from 41 patients with trophoblastic tumour were analysed. Pregnancy-specific beta-1 glycoprotein (SP1), human chorionic gonadotropin (hCG), and placental protein 5 (PP5) were measured by specific radioimmunoassay. Pregnancy-associated α2-glycoprotein (α2-PAG) was measured by electroimmunoassay. SP1 and hCG levels were high in 36 and 35 patients respectively; α2-PAG concentration was also high in 29 patients. PP5 was found only in patients with a hydatidiform mole and it disappeared from serum within a few hours of evacuation. SP1 and hCG levels decreased during the course of the treatment but seronegativity was reached only after some months; hCG was still detectable after that and disappeared from the serum more slowly. Both parameters were sensitive indicators of residual tumour activity and indicated the need more effective treatment some months before clinical manifestations of recurrence became evident. In some patients only one of the tumour markers was present during follow-up, indicating the importance of careful monitoring including the measurement of serum SP1 and hCG levels. A positive correlation between α2-PAG and hCG, SP1 and the clinical course was found only in 80% of patients a finding which demonstrates the limited value of α2-PAG measurements.

KW - Follow-up investigations

KW - Pregnancy and placental proteins

KW - Pregnancy-specific and pregnancy-associated proteins

KW - Trophoblastic tumours

UR - http://www.scopus.com/inward/record.url?scp=0019730668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019730668&partnerID=8YFLogxK

U2 - 10.1007/BF02110021

DO - 10.1007/BF02110021

M3 - Article

C2 - 6174083

AN - SCOPUS:0019730668

VL - 231

SP - 33

EP - 39

JO - Archiv fur Gynakologie

JF - Archiv fur Gynakologie

SN - 0932-0067

IS - 1

ER -